Enanta Pharmaceuticals In... (ENTA)
NASDAQ: ENTA
· Real-Time Price · USD
10.95
-1.02 (-8.52%)
At close: Oct 01, 2025, 1:46 PM
-8.52% (1D)
| Bid | 10.93 |
| Market Cap | 234.08M |
| Revenue (ttm) | 64.81M |
| Net Income (ttm) | -92.01M |
| EPS (ttm) | -6.55 |
| PE Ratio (ttm) | -1.67 |
| Forward PE | -4.99 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 10.97 |
| Volume | 2,881,011 |
| Avg. Volume (20D) | 501,066 |
| Open | 10.22 |
| Previous Close | 11.97 |
| Day's Range | 9.91 - 11.81 |
| 52-Week Range | 4.09 - 15.34 |
| Beta | 0.84 |
| Ex-Dividend Date | n/a |
About ENTA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol ENTA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for ENTA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsEnanta Pharmaceuticals Inc. is scheduled to release its earnings on
Nov 24, 2025,
after market closes.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
21 hours ago
-21.04%
Enanta Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
2 days ago
+91.9%
Enanta Pharmaceuticals shares are trading higher after the company reported topline results from its Phase 2b study of Zelicapavir for RSV in high-risk adults.
22 hours ago · businesswire.com
Enanta Pharmaceuticals Announces Pricing of Upsized Public Offering of Common StockWATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for virology and immunology indications...
1 month ago · businesswire.com
Enanta Pharmaceuticals to Participate in September Investor ConferencesWATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and immunological ...
